Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Lexeo Therapeutics, Inc. (LXEO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.90-10.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LXEO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce losses and improve earnings over next two years | A supporting condition in Lexeo Therapeutics, Inc.'s published investment case. The stated target is EPS loss narrows from -$1.14 in 2026 to less negative in 2027. | Broken | EPS loss worsens beyond -$1.34 in 2027 | Diluted EPS: $-0.30 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$1.14 in 2026 to less negative in 2027. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-0.3 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, clinical-stage biotechnology thesis, where the case depends on trial progress and future regulatory steps rather than current profits. The thesis is on watch: management is on track with the LX2006 trial, but performance is weak, management execution has been volatile, and overall confidence is low.
The evidence does not include a valuation measure or a clear account of what market expectations already assume, so whether LXEO looks cheap or expensive versus peers is unclear. The market-expectations gap cannot be assessed from this snapshot.
Near term, results remain weak and the risk of a miss is elevated; the next company update is an important check on execution. Over the multi-year view, LX2006 enrollment has started, with topline trial data expected in the second half of 2027 and a regulatory submission planned for the first half of 2028. Cash declined modestly through 2026-Q2, while management says runway extends into 2028; the acquisition adds to the platform but also adds execution demands.
The central swing factor is whether LX2006 advances on schedule and produces data that support the planned regulatory path. A guidance cut or further weakening in jobs data would add risk, while stronger results and guidance from major healthcare peers could support sector momentum. The Mantle acquisition’s progress and its fit within the stated cash runway also matter.
Over the next 1 to 3 years, LXEO remains a high-risk, event-driven long-term thesis with tangible trial progress but limited evidence of financial strength. The thesis hinges on clinical execution, cash discipline, and whether the new platform expansion delivers progress without disrupting the planned runway. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain cash, cash equivalents, and investments to support operations into 2028 | A primary condition in Lexeo Therapeutics, Inc.'s published investment case. The stated target is >= $227.6 million cash and equivalents. | Intact | cash falls below $200 million before 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Provide regulatory updates on LX2006 for Friedreich ataxia cardiomyopathy | It has regulatory progress on LX2006. | Intact | No regulatory updates or delays in LX2006 approval process | Qualitative: Regulatory pathway confirmed Seeking Alpha article confirms LX2006 has a viable regulatory pathway and timeline, reinforcing the approval path target. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.28 → $-1.34 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-07-25 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-07-26 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-07-27 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-07-28 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-07-29 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-07-30 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-07-31 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-01 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-02 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-03 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-04 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-05 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-06 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-07 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-08 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-09 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-10 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-12 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-13 | $-1.34 | $6,111,110 | 8 / 9 |
| 2026-08-14 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-15 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-16 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-17 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-18 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-19 | $-1.28 | $6,875,000 | 7 / 6 |
| 2026-08-20 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-21 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-22 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-23 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-24 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-25 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-26 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-27 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-28 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-29 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-30 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-08-31 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-01 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-02 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-03 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-04 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-05 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-06 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-07 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-08 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-09 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-10 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-11 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-12 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-13 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-14 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-15 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-16 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-17 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-18 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-19 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-20 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-21 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-22 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-23 | $-1.37 | $6,875,000 | 7 / 6 |
| 2026-09-24 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-09-25 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-09-26 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-09-27 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-09-28 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-09-29 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-09-30 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-01 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-02 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-03 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-04 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-05 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-06 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-07 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-08 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-09 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-10 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-11 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-12 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-13 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-14 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-15 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-16 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-17 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-18 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-19 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-20 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-21 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-22 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-23 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-24 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-25 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-26 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-27 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-28 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-29 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-30 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-10-31 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-11-01 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-11-02 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-11-03 | $-1.34 | $6,875,000 | 7 / 6 |
| 2026-11-04 | $-1.34 | $6,875,000 | 7 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.